{"id":"ciprofloxacin-triple-dose","safety":{"commonSideEffects":[{"rate":"3-17%","effect":"Nausea"},{"rate":"2-16%","effect":"Diarrhea"},{"rate":"1-2%","effect":"Vomiting"},{"rate":"1-7%","effect":"Abdominal pain"},{"rate":"1-2%","effect":"Headache"},{"rate":"<1%","effect":"Tendinopathy/tendon rupture"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ciprofloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This leads to accumulation of DNA breaks, cell death, and bactericidal activity. The 'triple dose' designation likely refers to a higher dosing regimen being evaluated in Phase 3 trials, potentially for serious infections or resistant pathogens.","oneSentence":"Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:58.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (specific indication for triple-dose formulation in Phase 3 unknown; historically used for respiratory, urinary, gastrointestinal, and skin infections)"}]},"trialDetails":[{"nctId":"NCT01733966","phase":"PHASE3","title":"A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults","status":"TERMINATED","sponsor":"Quanta Medical","startDate":"2010-05","conditions":"Diverticular Sigmoïditis","enrollment":100},{"nctId":"NCT00670215","phase":"PHASE3","title":"BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-04","conditions":"Bacterial Infections","enrollment":497}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ciprofloxacin triple dose","genericName":"Ciprofloxacin triple dose","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Bacterial infections (specific indication for triple-dose formulation in Phase 3 unknown; historically used for respiratory, urinary, gastrointestinal, and skin infections).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}